SPDR S&P Biotech ETF $XBI Shares Purchased by Viewpoint Capital Management LLC

Viewpoint Capital Management LLC raised its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 42.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the exchange traded fund’s stock after buying an additional 3,000 shares during the period. Viewpoint Capital Management LLC’s holdings in SPDR S&P Biotech ETF were worth $829,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. JPMorgan Chase & Co. raised its position in shares of SPDR S&P Biotech ETF by 625.1% during the 1st quarter. JPMorgan Chase & Co. now owns 10,369,706 shares of the exchange traded fund’s stock worth $840,983,000 after acquiring an additional 12,344,558 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in SPDR S&P Biotech ETF by 33.0% in the first quarter. Goldman Sachs Group Inc. now owns 13,524,858 shares of the exchange traded fund’s stock valued at $1,096,866,000 after purchasing an additional 3,353,029 shares in the last quarter. Simplex Trading LLC increased its stake in SPDR S&P Biotech ETF by 116.1% in the first quarter. Simplex Trading LLC now owns 241,039 shares of the exchange traded fund’s stock valued at $19,548,000 after purchasing an additional 1,741,445 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in SPDR S&P Biotech ETF in the first quarter valued at approximately $85,155,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in SPDR S&P Biotech ETF during the first quarter worth approximately $48,660,000.

SPDR S&P Biotech ETF Trading Up 0.0%

Shares of NYSEARCA:XBI opened at $103.64 on Tuesday. The firm has a 50 day simple moving average of $92.44 and a 200-day simple moving average of $85.25. The company has a market capitalization of $6.15 billion, a PE ratio of 11.47 and a beta of 0.97. SPDR S&P Biotech ETF has a twelve month low of $66.66 and a twelve month high of $105.47.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.